Glycine/lysine acetylsalicylate inhalation - Ventaleon

Drug Profile

Glycine/lysine acetylsalicylate inhalation - Ventaleon

Alternative Names: Acti-INSP-001; Glycine/lysine acetylsalicylate inhalation - Vectura; LASAG; Lysine acetylsalicylate glycine inhalation - Vectura; Lysine acetylsalicylate/glycine inhalation - Vectura; VR 736

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator Activaero GmbH
  • Developer Vectura; Ventaleon
  • Class Antiplatelets; Antipyretics; Antirheumatics; Antivirals; Basic amino acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 29 Jul 2016 Glycine/lysine acetylsalicylate inhalation is still in phase II trials in Influenza virus infections (in hospitalised patients) (Vectura pipeline, July 2016)
  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
  • 12 Feb 2013 Phase-II clinical trials in Influenza virus infections (in hospitalised patients) in Latvia, Lithuania and Spain (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top